Literature DB >> 8973841

Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum.

T Takahashi1, H Yamashita, Y X Zhang, S Nakamura.   

Abstract

In the present study, we examined the effect of amantadine on extracellular dopamine levels in the rat striatum using an in vivo microdialysis. Perfusion of amantadine (0.1-1 mM) through the microdialysis probe caused an increase both in extracellular dopamine and glutamate levels in rat striatum. Amantadine was found to increase extracellular dopamine concentration in Ca(2+)-dependent manner, but the effect was not abolished by omega-conotoxin. Although intraperitoneal administration of MK-801 [(+)-5-methyl-10, 11-dihydroxy-5H-dibenzo (a,d)cyclohepten-5,10-imine] alone could not significantly alter the concentration of dopamine, it attenuated amantadine-induced increase in dopamine level. These findings suggest that an interaction between dopaminergic and glutamatergic neurotransmission is an important component in the regulation of striatal dopamine levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973841     DOI: 10.1016/s0361-9230(96)00211-0

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  7 in total

Review 1.  Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

Review 2.  Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?

Authors:  Sarah Marmol; Matthew Feldman; Carlos Singer; Jason Margolesky
Journal:  CNS Drugs       Date:  2021-10-14       Impact factor: 5.749

3.  Differential effects of D-cycloserine and amantadine on motor behavior and D2/3 receptor binding in the nigrostriatal and mesolimbic system of the adult rat.

Authors:  Susanne Nikolaus; Hans-Jörg Wittsack; Frithjof Wickrath; Anja Müller-Lutz; Hubertus Hautzel; Markus Beu; Christina Antke; Eduards Mamlins; Maria Angelica De Souza Silva; Joseph P Huston; Gerald Antoch; Hans-Wilhelm Müller
Journal:  Sci Rep       Date:  2019-11-06       Impact factor: 4.379

Review 4.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003

5.  Amantadine in the treatment of pathological gambling: a case report.

Authors:  Mauro Pettorruso; Giovanni Martinotti; Marco Di Nicola; Marco Onofrj; Massimo Di Giannantonio; Gianluigi Conte; Luigi Janiri
Journal:  Front Psychiatry       Date:  2012-11-27       Impact factor: 4.157

6.  Amantadine ameliorates dopamine-releasing deficits and behavioral deficits in rats after fluid percussion injury.

Authors:  Eagle Yi-Kung Huang; Pi-Fen Tsui; Tung-Tai Kuo; Jing-Jr Tsai; Yu-Ching Chou; Hsin-I Ma; Yung-Hsiao Chiang; Yuan-Hao Chen
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

Review 7.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.